Clinical trial starts statistics 2026

Alzheimer's disease drug trial starts

The best-covered measure of clinical trial starts. Every point opens its record; the values are one click away under the chart.

Fig 1 · C21 · Alzheimer's disease drug trial starts Annual

Alzheimer's disease drug trial starts by region

3 regions, 2020 to 2025

3 regions · 18 observations · 2020 to 2025

View the underlying data

Alzheimer's disease drug trial starts by region
Region	Period	Type	Value
Global	2025	Actual	78
Global	2024	Actual	71
Global	2023	Actual	58
Global	2022	Actual	81
Global	2021	Actual	87
Global	2020	Actual	66
United States	2025	Actual	34
United States	2024	Actual	38
United States	2023	Actual	30
United States	2022	Actual	50
United States	2021	Actual	56
United States	2020	Actual	37
China	2025	Actual	16
China	2024	Actual	14
China	2023	Actual	5
China	2022	Actual	11
China	2021	Actual	12
China	2020	Actual	6

Source: ClinicalTrials.gov · CC BY 4.0 · statorigin.org

Embed

Free to embed, including commercially. The attribution bar is part of the chart; it is what keeps the data citable.

<iframe src="https://statorigin.org/embed/pharmaceuticals--ctgov-alz-trial-starts--regions" width="100%" height="380" style="border:1px solid #e2e5e3;border-radius:8px" title="Alzheimer's disease drug trial starts by region" loading="lazy"></iframe>
<p><a href="https://statorigin.org/statistics/clinical-trial-starts">Alzheimer's disease drug trial starts by region</a>, data from StatOrigin, CC BY 4.0</p>

Preview embed

Fig 2 · C21 · Latest by region

Alzheimer's disease drug trial starts by region

Latest value per region, 2025

3 entries

View the underlying data

Alzheimer's disease drug trial starts by region
Category	Source	Type	Value
Global	ClinicalTrials.gov	Actual	78
United States	ClinicalTrials.gov	Actual	34
China	ClinicalTrials.gov	Actual	16

Source: ClinicalTrials.gov · CC BY 4.0 · statorigin.org

Embed

Free to embed, including commercially. The attribution bar is part of the chart; it is what keeps the data citable.

<iframe src="https://statorigin.org/embed/pharmaceuticals--ctgov-alz-trial-starts--by-region" width="100%" height="380" style="border:1px solid #e2e5e3;border-radius:8px" title="Alzheimer's disease drug trial starts by region" loading="lazy"></iframe>
<p><a href="https://statorigin.org/statistics/clinical-trial-starts">Alzheimer's disease drug trial starts by region</a>, data from StatOrigin, CC BY 4.0</p>

Preview embed

Every measure of clinical trial starts

127 measures: the same subject cut by product, segment, basis or form. Each has its own page with every record.

Measure	Latest	Where and when	Records
Alzheimer's disease drug trial starts	269	Global, 1 Jan 2023 to 27 Sep 2026	21
Antibody-drug conjugate trial starts	1,225	Global, 1 Jan 2023 to 27 Sep 2026	21
Autoimmune cell therapy and T-cell engager trial starts	300	Global, 1 Jan 2023 to 27 Sep 2026	21
Cardiometabolic RNA and next-generation lipid drug trial starts	128	Global, 1 Jan 2023 to 27 Sep 2026	21
Gene editing trial starts	133	Global, 1 Jan 2023 to 27 Sep 2026	21
GLP-1, incretin multi-agonist and amylin trial starts	798	Global, 1 Jan 2023 to 27 Sep 2026	21
Inflammatory bowel disease drug trial starts	373	Global, 1 Jan 2023 to 27 Sep 2026	21
KRAS and RAS inhibitor trial starts	226	Global, 1 Jan 2023 to 27 Sep 2026	21
Oncology bispecific antibody trial starts	985	Global, 1 Jan 2023 to 27 Sep 2026	21
Radioligand therapy trial starts	291	Global, 1 Jan 2023 to 27 Sep 2026	21
Phase I small molecule clinical trial share	62%	Global, 2025	6
Large company small molecule share of Phase I clinical trial starts	66%	Global, 2025	4
Cell and gene therapy clinical trial starts	631	Global, 2023	2
Oncology clinical trial starts growth rate	-4%	Global, 2025	2
Phase I immunology clinical trial starts growth rate	-13%	Global, 2025	2
Phase II immunology clinical trial starts growth rate	14%	Global, 2025	2
Phase II oncology clinical trial starts growth rate	3%	Global, 2025	2
Phase III immunology clinical trial starts growth rate	-4%	Global, 2025	2
Phase III oncology clinical trial starts growth rate	4%	Global, 2025	2
Antibody-drug conjugate trial starts since 2023: Breast cancer	315	Global, 1 Jan 2023 to 27 Sep 2026	1
Antibody-drug conjugate trial starts since 2023: Gastric or oesophageal cancer	121	Global, 1 Jan 2023 to 27 Sep 2026	1
Antibody-drug conjugate trial starts since 2023: Lung cancer	193	Global, 1 Jan 2023 to 27 Sep 2026	1
Antibody-drug conjugate trial starts since 2023: Lymphoma	119	Global, 1 Jan 2023 to 27 Sep 2026	1
Antibody-drug conjugate trial starts since 2023: Ovarian, cervical or endometrial cancer	195	Global, 1 Jan 2023 to 27 Sep 2026	1
Antibody-drug conjugate trial starts since 2023: Urothelial or bladder cancer	116	Global, 1 Jan 2023 to 27 Sep 2026	1
Autoimmune cell therapy and T-cell engager trial starts since 2023: Immune thrombocytopenia or autoimmune haemolytic anaemia	26	Global, 1 Jan 2023 to 27 Sep 2026	1
Autoimmune cell therapy and T-cell engager trial starts since 2023: Multiple sclerosis	25	Global, 1 Jan 2023 to 27 Sep 2026	1
Autoimmune cell therapy and T-cell engager trial starts since 2023: Myasthenia gravis	29	Global, 1 Jan 2023 to 27 Sep 2026	1
Autoimmune cell therapy and T-cell engager trial starts since 2023: Systemic lupus erythematosus / lupus nephritis	147	Global, 1 Jan 2023 to 27 Sep 2026	1
Autoimmune cell therapy and T-cell engager trial starts since 2023: Systemic sclerosis	68	Global, 1 Jan 2023 to 27 Sep 2026	1
Autoimmune cell therapy and T-cell engager trial starts since 2023: Vasculitis	39	Global, 1 Jan 2023 to 27 Sep 2026	1
Gene editing trial starts since 2023: Cancer	36	Global, 1 Jan 2023 to 27 Sep 2026	1
Gene editing trial starts since 2023: Inherited eye disease	5	Global, 1 Jan 2023 to 27 Sep 2026	1
Gene editing trial starts since 2023: Inherited liver and metabolic disease	17	Global, 1 Jan 2023 to 27 Sep 2026	1
Gene editing trial starts since 2023: Sickle cell disease or beta-thalassaemia	18	Global, 1 Jan 2023 to 27 Sep 2026	1
GLP-1, incretin multi-agonist and amylin trial starts since 2023: Alcohol or substance use	31	Global, 1 Jan 2023 to 27 Sep 2026	1
GLP-1, incretin multi-agonist and amylin trial starts since 2023: Chronic kidney disease	21	Global, 1 Jan 2023 to 27 Sep 2026	1
GLP-1, incretin multi-agonist and amylin trial starts since 2023: Heart failure or cardiovascular disease	73	Global, 1 Jan 2023 to 27 Sep 2026	1
GLP-1, incretin multi-agonist and amylin trial starts since 2023: MASH / NASH	33	Global, 1 Jan 2023 to 27 Sep 2026	1
GLP-1, incretin multi-agonist and amylin trial starts since 2023: Obesity or overweight	468	Global, 1 Jan 2023 to 27 Sep 2026	1
GLP-1, incretin multi-agonist and amylin trial starts since 2023: Type 2 diabetes	228	Global, 1 Jan 2023 to 27 Sep 2026	1
Inflammatory bowel disease drug trial starts since 2023: Crohn's disease	154	Global, 1 Jan 2023 to 27 Sep 2026	1
Inflammatory bowel disease drug trial starts since 2023: Ulcerative colitis	224	Global, 1 Jan 2023 to 27 Sep 2026	1
KRAS and RAS inhibitor trial starts since 2023: Advanced solid tumours (basket)	89	Global, 1 Jan 2023 to 27 Sep 2026	1
KRAS and RAS inhibitor trial starts since 2023: Colorectal cancer	55	Global, 1 Jan 2023 to 27 Sep 2026	1
KRAS and RAS inhibitor trial starts since 2023: Non-small cell lung cancer	93	Global, 1 Jan 2023 to 27 Sep 2026	1
KRAS and RAS inhibitor trial starts since 2023: Pancreatic cancer	79	Global, 1 Jan 2023 to 27 Sep 2026	1
Oncology bispecific antibody trial starts since 2023: Breast cancer	51	Global, 1 Jan 2023 to 27 Sep 2026	1
Oncology bispecific antibody trial starts since 2023: Gastric, oesophageal or colorectal cancer	156	Global, 1 Jan 2023 to 27 Sep 2026	1
Oncology bispecific antibody trial starts since 2023: Liver or biliary cancer	60	Global, 1 Jan 2023 to 27 Sep 2026	1
Oncology bispecific antibody trial starts since 2023: Lung cancer	194	Global, 1 Jan 2023 to 27 Sep 2026	1
Oncology bispecific antibody trial starts since 2023: Lymphoma	184	Global, 1 Jan 2023 to 27 Sep 2026	1
Oncology bispecific antibody trial starts since 2023: Multiple myeloma	132	Global, 1 Jan 2023 to 27 Sep 2026	1
Oncology clinical trial starts	2,162	Global, 2024	1
Oncology share of all clinical trials	41%	Global, 2024	1
Radioligand therapy trial starts since 2023: Breast cancer	25	Global, 1 Jan 2023 to 27 Sep 2026	1
Radioligand therapy trial starts since 2023: Kidney cancer	13	Global, 1 Jan 2023 to 27 Sep 2026	1
Radioligand therapy trial starts since 2023: Lung cancer	25	Global, 1 Jan 2023 to 27 Sep 2026	1
Radioligand therapy trial starts since 2023: Neuroendocrine tumours	49	Global, 1 Jan 2023 to 27 Sep 2026	1
Radioligand therapy trial starts since 2023: Prostate cancer	145	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Actinium-225 agents (alpha)	48	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Adagrasib (G12C)	25	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Agitation and psychosis in Alzheimer's	7	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Allogeneic or universal	72	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Amivantamab (EGFR x MET)	32	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Amycretin	22	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: ANGPTL3 (zodasiran, solbinsiran)	4	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Anti-amyloid antibodies (all)	21	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Anti-integrin (vedolizumab and others)	24	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Anti-TL1A antibodies	21	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: APOC3 (olezarsen, plozasiran)	7	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Base editing	35	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: BCMA x CD3 T-cell engagers	99	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: BCMA-directed	96	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: BL-B01D1 (EGFR x HER3 bispecific ADC)	55	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Cadonilimab (PD-1 x CTLA-4)	184	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: CagriSema / cagrilintide	41	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: CAR-NK	25	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: CD19-directed	195	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: CD20 x CD3 T-cell engagers	142	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Daraxonrasib (pan-RAS)	15	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Datopotamab deruxtecan (TROP2)	29	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Disitamab vedotin (HER2)	120	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Divarasib (G12C)	8	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Donanemab	8	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Enfortumab vedotin (Nectin-4)	60	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Ex vivo edited stem cells (sickle cell, thalassaemia)	18	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Garsorasib, fulzerasib and glecirasib (G12C)	31	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Gene-edited CAR-T or TCR-T	42	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: GLP-1 receptor agonists	5	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: IL-23 p19 antibodies	42	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: In vivo liver editing (LNP)	10	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Inclisiran (PCSK9 siRNA)	32	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Ivonescimab (PD-1 x VEGF)	153	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: JAK inhibitors	20	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: KRAS G12D-directed agents (inhibitors, degraders, vaccines, cell therapies)	90	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Lead-212 agents (alpha)	11	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Lecanemab	9	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Lp(a) lowering (olpasiran, lepodisiran, zerlasiran, pelacarsen, muvalaplin)	14	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Lutetium-177 agents	222	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: MariTide	25	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Mazdutide	31	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Obefazimod	3	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Obicetrapib (CETP)	13	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Olomorasib (G12C)	14	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Oral IL-23 receptor peptide (icotrokinra)	3	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Oral PCSK9 inhibitors (enlicitide, AZD0780)	45	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Orforglipron	39	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: PD-(L)1 x VEGF bispecifics (all)	204	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: PSMA-targeted	98	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Pumitamig / BNT327 (PD-L1 x VEGF)	36	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Radium-223	8	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Retatrutide	25	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: S1P modulators	6	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Sacituzumab govitecan (TROP2)	98	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Sacituzumab tirumotecan (TROP2)	105	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Semaglutide	365	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: SHR-A1811 / trastuzumab rezetecan (HER2)	109	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Somatostatin-receptor-targeted	45	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Sotorasib (G12C)	28	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: T-cell engagers	17	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Tarlatamab (DLL3 x CD3)	30	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Tau-targeted therapies	6	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Tirzepatide	184	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Trastuzumab deruxtecan (HER2)	139	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: Trontinemab (brain shuttle)	2	Global, 1 Jan 2023 to 27 Sep 2026	1
Trial starts since 2023: TTR silencers (vutrisiran, patisiran, eplontersen, nucresiran)	6	Global, 1 Jan 2023 to 27 Sep 2026	1

Clinical trial starts by country

A page for every country with at least three records:

Frequently asked questions

What does clinical trial starts measure?

Total number of clinical trials initiated during a given period.

What is the latest alzheimer's disease drug trial starts?

Global: 78 in 2025, +9.9% on 2024.

Which countries does this clinical trial starts data cover?

2 countries, with a page each for China, United States.

Where does the data come from?

From 320 documents published by ClinicalTrials.gov and IQVIA. Every figure links to its record, which quotes the sentence or table row it was read from.

How often is it updated?

Annual; the newest figure covers 2025, and the next release should cover 2026.

Sources

320 documents from 2 publishers; the 20 largest are listed. Each links to the publisher's own copy.

Document	Publisher	Published	Data points
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in any country	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in any country	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in any country	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in any country	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in any country	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in any country	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in any country	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in China	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in China	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in China	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in China	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in China	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in China	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2020-01-01 to 2020-12-31, with sites in at least one site in China	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2025-01-01 to 2025-12-31, with sites in at least one site in the United States	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2024-01-01 to 2024-12-31, with sites in at least one site in the United States	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2023-12-31, with sites in at least one site in the United States	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2023-01-01 to 2026-09-27, with sites in at least one site in the United States	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2022-01-01 to 2022-12-31, with sites in at least one site in the United States	ClinicalTrials.gov	—	1
ClinicalTrials.gov study count: Interventional drug or biologic studies in Alzheimer's disease with a start date from 2021-01-01 to 2021-12-31, with sites in at least one site in the United States	ClinicalTrials.gov	—	1

Cite this page

Published under CC BY 4.0: free to reuse, including commercially, with attribution to StatOrigin and the original publisher. To cite one figure, open its record.

APA MLA Chicago BibTeX

StatOrigin. (2026). Clinical trial starts statistics [Data set]. Retrieved September 29, 2026, from https://statorigin.org/statistics/clinical-trial-starts

"Clinical trial starts statistics." StatOrigin, 2026, https://statorigin.org/statistics/clinical-trial-starts. Accessed 29 Sep. 2026.

StatOrigin. "Clinical trial starts statistics." Data set, 2026. Accessed September 29, 2026. https://statorigin.org/statistics/clinical-trial-starts.

@misc{statorigin_clinical_trial_starts_2026, title = {Clinical trial starts statistics}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/statistics/clinical-trial-starts}, note = {Data set. Accessed 2026-09-29} }

More pharmaceuticals statistics

All statistics topics →